Therefore, understanding the regulation mechanisms of mTOR and S6K1 activities during RP progression might lead to development of therapeutic approaches centered around S6K1 activation for treating patients who suffer from retinal degeneration. This evidence concerns the gene RPS6KB1 and retinitis pigmentosa 1.